The role of FDG-PET-CT is limited in initial staging of nodal metastasis for thin cutaneous melanoma

Am J Surg. 2021 Apr;221(4):737-740. doi: 10.1016/j.amjsurg.2020.03.031. Epub 2020 Apr 7.

Abstract

Introduction: Positron emission tomography computed tomography (PET-CT) is often used to stage nodal metastases in thin cutaneous melanoma, with limited evidence.

Methods: A retrospective review of patients with cutaneous malignant melanoma treated at our institution was performed from 2005 to 2015, identifying those who received a PET-CT prior to lymphadenectomy. Biopsy features, lymph node status, and PET-CT results were collected. We calculated the overall sensitivity, specificity, accuracy, likelihood ratios, and positive predictive value of PET-CT in identifying nodal metastases. Results were stratified by initial biopsy tumor depth.

Results: We identified 367 cases; 95 obtained a PET-CT prior to lymphadenectomy. Overall, sensitivity and specificity of PET-CT was 34.6% and 95.4%, respectively. The positive likelihood ratio and negative likelihood ratio were 7.62 and 0.68, respectively. The accuracy was 78.2%. The positive predictive value for T3 and T4 melanomas were 100% and 81.4%, respectively. For thin melanomas, specificity and accuracy was 88.2% and 88.2%, respectively.

Conclusions: PET-CT has low specificity and its use alone is not recommended for initial staging of nodal metastases in thin cutaneous malignant melanoma.

Keywords: Cutaneous melanoma; Metastases; Nodal basin; Positron emission tomography; Screening; Thin melanoma.

MeSH terms

  • Biopsy
  • Cutaneous Malignant Melanoma
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Lymphatic Metastasis / diagnostic imaging*
  • Male
  • Melanoma / diagnostic imaging*
  • Melanoma / pathology
  • Middle Aged
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography*
  • Predictive Value of Tests
  • Radiopharmaceuticals
  • Retrospective Studies
  • Sensitivity and Specificity
  • Skin Neoplasms / diagnostic imaging*
  • Skin Neoplasms / pathology

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18